IMGN
ImmunoGen Inc
Price:  
31.23 
USD
Volume:  
49,500,900.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

IMGN WACC - Weighted Average Cost of Capital

The WACC of ImmunoGen Inc (IMGN) is 8.9%.

The Cost of Equity of ImmunoGen Inc (IMGN) is 8.90%.
The Cost of Debt of ImmunoGen Inc (IMGN) is 4.25%.

Range Selected
Cost of equity 6.80% - 11.00% 8.90%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 4.00% - 4.50% 4.25%
WACC 6.8% - 10.9% 8.9%
WACC

IMGN WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.64 1.09
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.80% 11.00%
Tax rate 26.20% 27.00%
Debt/Equity ratio 0 0
Cost of debt 4.00% 4.50%
After-tax WACC 6.8% 10.9%
Selected WACC 8.9%

IMGN's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for IMGN:

cost_of_equity (8.90%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.64) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.